243 related articles for article (PubMed ID: 32794199)
1. Proteinase 3 Autoreactivity in Anti-Neutrophil Cytoplasmic Antibody-associated vasculitis-Immunological versus clinical features.
Sharma RK; Lövström B; Gunnarsson I; Malmström V
Scand J Immunol; 2020 Nov; 92(5):e12958. PubMed ID: 32794199
[TBL] [Abstract][Full Text] [Related]
2. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
3. An unusual presentation of propylthiouracil-induced anti-MPO and PR3 positive ANCA vasculitis with associated anti-GBM antibodies, IgA nephropathy and an IgG4 interstitial infiltrate: a case report.
Galante JR; Daruwalla CP; Roberts ISD; Haynes R; Storey BC; Bottomley MJ
BMC Nephrol; 2020 Jul; 21(1):295. PubMed ID: 32703233
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
5. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
Mohammad AJ; Segelmark M
J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Bornstein G; Ben-Zvi I; Furie N; Grossman C
Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
[TBL] [Abstract][Full Text] [Related]
8. Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
Wallace ZS; Stone JH
Front Immunol; 2019; 10():2855. PubMed ID: 31867013
[TBL] [Abstract][Full Text] [Related]
9. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
[TBL] [Abstract][Full Text] [Related]
10. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
12. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
[TBL] [Abstract][Full Text] [Related]
13. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of PR3-ANCA associated vasculitis.
Kallenberg CG
J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
[TBL] [Abstract][Full Text] [Related]
15. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
Front Immunol; 2021; 12():737708. PubMed ID: 34759920
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
17. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
18. Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.
Hong Y; Shi P; Liu X; Yang L; Li K; Xu F; Liang S; Liu Z; Zhang H; Chen Y; Hu W
Clin Rheumatol; 2019 Jun; 38(6):1665-1673. PubMed ID: 30737591
[TBL] [Abstract][Full Text] [Related]
19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.
Bonaci-Nikolic B; Andrejevic S; Pavlovic M; Dimcic Z; Ivanovic B; Nikolic M
Clin Rheumatol; 2010 Aug; 29(8):893-904. PubMed ID: 20306213
[TBL] [Abstract][Full Text] [Related]
20. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
